GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Caliway Biopharmaceuticals Co Ltd (ROCO:6919) » Definitions » EV-to-FCF

Caliway Biopharmaceuticals Co (ROCO:6919) EV-to-FCF : -151.49 (As of Jun. 20, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Caliway Biopharmaceuticals Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Caliway Biopharmaceuticals Co's Enterprise Value is NT$65,690.62 Mil. Caliway Biopharmaceuticals Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-433.62 Mil. Therefore, Caliway Biopharmaceuticals Co's EV-to-FCF for today is -151.49.

The historical rank and industry rank for Caliway Biopharmaceuticals Co's EV-to-FCF or its related term are showing as below:

ROCO:6919' s EV-to-FCF Range Over the Past 10 Years
Min: -202.14   Med: -130.41   Max: -40.41
Current: -147.63

During the past 5 years, the highest EV-to-FCF of Caliway Biopharmaceuticals Co was -40.41. The lowest was -202.14. And the median was -130.41.

ROCO:6919's EV-to-FCF is ranked worse than
100% of 397 companies
in the Biotechnology industry
Industry Median: 6.29 vs ROCO:6919: -147.63

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-20), Caliway Biopharmaceuticals Co's stock price is NT$496.50. Caliway Biopharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-3.940. Therefore, Caliway Biopharmaceuticals Co's PE Ratio for today is At Loss.


Caliway Biopharmaceuticals Co EV-to-FCF Historical Data

The historical data trend for Caliway Biopharmaceuticals Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Caliway Biopharmaceuticals Co EV-to-FCF Chart

Caliway Biopharmaceuticals Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - - -25.13 -53.41

Caliway Biopharmaceuticals Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial - - -25.13 - -53.41

Competitive Comparison of Caliway Biopharmaceuticals Co's EV-to-FCF

For the Biotechnology subindustry, Caliway Biopharmaceuticals Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Caliway Biopharmaceuticals Co's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Caliway Biopharmaceuticals Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Caliway Biopharmaceuticals Co's EV-to-FCF falls into.



Caliway Biopharmaceuticals Co EV-to-FCF Calculation

Caliway Biopharmaceuticals Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=65690.615/-433.624
=-151.49

Caliway Biopharmaceuticals Co's current Enterprise Value is NT$65,690.62 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Caliway Biopharmaceuticals Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-433.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Caliway Biopharmaceuticals Co  (ROCO:6919) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Caliway Biopharmaceuticals Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=496.50/-3.940
=At Loss

Caliway Biopharmaceuticals Co's share price for today is NT$496.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Caliway Biopharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-3.940.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Caliway Biopharmaceuticals Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Caliway Biopharmaceuticals Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Caliway Biopharmaceuticals Co (ROCO:6919) Business Description

Traded in Other Exchanges
N/A
Address
No.99, Sec. 1, Xintai 5th Road, 32F.-9, Xizhi District, New Taipei City, TWN, 221
Caliway Biopharmaceuticals Co Ltd is specialized in the development of new drugs for medical aesthetic and inflammatory diseases. Its leading candidate, CBL-514, is a new drug that can trigger adipocyte apoptosis at the injection site and effectively reduce subcutaneous fat without causing tissue necrosis or prominent side effects.

Caliway Biopharmaceuticals Co (ROCO:6919) Headlines

No Headlines